The Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 (H.R.5333) passed the House and was placed on the Senate’s legislative calendar. The bill amends the FD&C Act to clarify the regulatory framework with respect to certain nonprescription drugs and authorizes the assessment and use of fees related to OTC monograph drug activities.
[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
